Dr. Sklar came to New Mexico to lead the National Flow Cytometry Resource at Los Alamos National Lab and to develop a biotechnology research program at the University of New Mexico. Beginning in 1998, Sklar and teams of colleagues and collaborators developed high throughput flow cytometry for drug discovery. The resulting patents led to 1) the formation of the startup company IntelliCyt which was bought by Sartorius, an international biotech company; 2) startup companies and clinical trials for membrane steroid receptors and the repurposing of ketorolac; 3) real-time methods to examine receptors in cell adhesion. The team used high throughput flow cytometry for small molecule discovery in the NIH Roadmap Molecular Libraries Program which served as the basis for the formation of the UNM Center for Molecular discovery and contributed at UNM to the Comprehensive Cancer Center, the Clinical and Translational Science Center, and the NCI Experimental Therapeutics Program.
Recognition of Sklar’s activities include UNM awards for Excellence in Basic Science, as Lobo Rainforest Innovation Fellow and Lifetime Achievement Award, UNM Presidential Award of Distinction, as well AIMBE and National Academy of Inventors Fellow. Dr. Sklar is currently Distinguished Professor Emeritus.
Larry A. Sklar、Ph.D。
イノベーション、ディスカバリー、トレーニングコンプレックス(IDTC)
部屋2140
700カミノデサラードNE
1ニューメキシコ大学
ニューメキシコ州アルバカーキ
87131-0001
電話番号: 505-272-6892
Email: lsklar@salud.unm.edu